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Editorial on the Research Topic
Tumor Heterogeneity
Cancer should not be considered just as an agglomerate of cells, but rather as a complex
morpho-functional entity with different compartments, which represent all together the so-called
intratumor heterogeneity (ITH), often difficult to identify using a morphological approach alone.
In the era of personalized medicine, the identification of ITH is an emerging issue for pathologists
because it is strongly related to clinical oncology influencing clinical presentation, symptoms,
behavior, tumor classification, and response to therapy (1, 2). ITH is a spatial and temporal
phenomenon generally distinct into two parts: clonal heterogeneity, which is due to the different
distribution of molecular alterations, and non-clonal heterogeneity that depends on the interaction
between tumor and surrounding microenvironment. Stanta and Bonin have clearly summarized
the different levels of ITH, which include a wide spectrum ofmolecular alterations (genemutations,
promoter genes methylation, copy number alterations) that directly influence morphological
differentiation, immunophenotype and, in turn, clinical presentation, biological aggressiveness,
and response to therapy.
In addition to ITH, the concept of tumor heterogeneity (TH) also includes intertumor
heterogeneity. It has been referred either to the differences observed between a primary cancer and
related metastases in the same patient or to the differences observed in different patients bearing
tumors with the same morphological features and consequently diagnosed under the same specific
entity (also defined interpatient heterogeneity) (3, 4).
The diagnostic impact of both intra- and inter-tumor heterogeneity must be taken into account
by both pathologists and clinicians. Indeed, the representativeness of small biopsy samples and fine
needle aspirates might be challenged by tumors with a strong degree of ITH. Results obtained by the
examination of only one tumor site in disseminated metastatic cancer disease might be not valid
in another tumor site from the same patient, i.e., between primary and metastases, or between
metastases. This is especially the case for metastases presenting long after the diagnosis of the
primary, hence the current debate about the importance, benefits and indications of “re-biopsies”
during the course of the disease.
Breast cancer is an excellent example of both intra and intertumor heterogeneity that
strongly influence the choice of the more appropriate clinical management. This mainly
depends on the evaluation of several different parameters, namely hormone receptors expression
and HER2 amplification, which can differ from patient to patients but also in areas of
the same tumor (spatial heterogeneity) also during its progression over time (temporal
heterogeneity) (Turashvili and Brogi).
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“Colorectal cancer is not just colorectal cancer” is a
tremendously effective paraphrase proposed by Blank et al.
to underlying that tumor heterogeneity, also in this context,
directly impacts the therapeutic strategy and patients’ outcome.
Colorectal carcinoma is an excellent example recapitulating
the large spectrum of clonal and, especially, non-clonal
heterogeneity. Non-clonal heterogeneity represented by tumor
interaction with the surrounding microenvironment reflects
some morphological features easily recognizable in routine H&E
preparations (i.e., vascularization, infiltrating-tumor associated
inflammatory cells, and tumor deposits in surrounding fat
tissue) and plays a pivotal role in tumor development directly
influencing gene expression in cancer cells.
TH is not a peculiar feature of solid tumors, but it plays a
pivotal role in the biology of lymphomas as well, representing a
key aspect that influences the clinical management at different
time points during the course of the disease. Magnoli et al. have
reviewed the molecular cytogenetic and immunohistochemical
heterogeneity of follicular lymphoma, a paradigmatic disease
traditionally considered as a single monolithic entity. Clusters
of gene mutations and deregulated epigenetic mechanisms
(clonal ITH), in concert with the interaction between neoplastic
lymphoid cells and microenvironment (non-clonal ITH),
determine the outcome and, consequently, greatly influence
the therapeutic choices. Data reported and critically reviewed
strongly suggest that follicular lymphoma is a plastic disease
from its early steps of development to progression and
final transformation.
TH is mainly referred to malignant neoplasms where it has
been largely investigated in the last years. However, it is worth
noting that TH is a phenomenon that may also play a crucial role
in benign neoplasms as described by Mete and Duan in benign
adrenocortical tumors. Specific genetic alterations determine
different histopathological features and greatly influence different
presentations of both primary hyperaldosteronism and Cushing
disease. This review clearly summarizes the genotype-phenotype
correlations elucidating the biological background of complex
endocrine diseases that can clinically present as different faces of
the same entity.
Once it has been established that tumor heterogeneity at its
different levels (molecular, immunophenotypic, morphological,
and clinical) represents a crucial point in the understanding of
tumor biology, the last but not least challenge for pathologists is
the methodological approach to its identification and evaluation
in daily routine practice. Tumor sampling methods follow
standardized and accepted protocols, which vary depending on
the specific topography (5). These protocols have been created
with the assumption that samples selected at gross examination
must be representative of the whole neoplasm. Although this
approach is true for diagnostic purposes, it clearly seems to
be inadequate to identify ITH. At this regard, Stanta and
Bonin describe a sampling procedure, which includes different
samples in the border, sub-border and central part of the tumor
with the aim to cover different areas as much as possible.
A similar approach is well-described by Cortés et al. who
describe in detail a multisite tumor sampling approach that
seems a promising technique useful to detect ITH, not adding
extra-costs and extra-time. Finally, it is worth noting that
liquid biopsy approaches are currently evaluated as promising
tools to overcome the limitations inherent to spatial and
temporal TH (6).
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